Filing Flows › Sutro Biopharma (STRO) › R&D spending
Sutro Biopharma (STRO) R&D spending by quarter
Sutro Biopharma's R&D spending was $31.7M in Q2 2026 (second quarter 2026), -13% from Q1 2026. Over the last 7 quarters it ranged from $31.7M (Q2 2026) to $71.0M (Q4 2024).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $31.7M | -13% | -17% |
| Q1 2026 | $36.6M | -0.2% | -29% |
| Q4 2025 | $36.6M | -8% | -48% |
| Q3 2025 | $39.9M | +4% | — |
| Q2 2025 | $38.3M | -26% | — |
| Q1 2025 | $51.6M | -27% | — |
| Q4 2024 | $71.0M | — | — |
Q2 2026 at a glance
Sutro Biopharma, Q2 2026: revenue $9.8M (-85% year over year), operating margin -303.8%, net loss $38.5M, operating cash flow −$38.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Sutro Biopharma's R&D spending?
Sutro Biopharma's R&D spending was $31.7M in Q2 2026 (second quarter 2026), -13% from Q1 2026.
How has Sutro Biopharma's R&D spending changed?
Over the last 7 quarters it ranged from $31.7M (Q2 2026) to $71.0M (Q4 2024).